Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-157 · 1 trial · 1 indication
Maximum observed plasma concentration (Cmax) of ABBV-157
Time to maximum observed plasma concentration (Tmax) of ABBV-157
Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of ABBV-157.
Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-157
The area under the plasma concentration-time curve over a dosing interval of tau (AUCtau).
Clearance is defined as the volume of plasma cleared of the drug per unit time.
Volume of Distribution (Vβ/F) of ABBV-157
Apparent Terminal phase elimination rate constant (β or Beta)
Terminal phase elimination half-life (t1/2) of ABBV-157
Fraction excreted unchanged in urine (fe)
Apparent Renal Clearance (CLR) of ABBV-157
Accumulation ratio for Cmax
Accumulation Ratio for AUCtau
Maximum observed plasma concentration (Cmax) of ABBV-157
Time to maximum observed plasma concentration (Tmax) of ABBV-157
Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of ABBV-157.
The area under the plasma concentration-time curve over a dosing interval of tau (AUCtau)
Clearance is defined as the volume of plasma cleared of the drug per unit time.
Volume of Distribution (Vβ/F) of ABBV-157
Apparent Terminal phase elimination rate constant (β or Beta)
Terminal phase elimination half-life (t1/2) of ABBV-157
Accumulation ratio for Cmax
Accumulation Ratio for AUCtau
Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-157
Psoriasis Area and Severity Index (PASI) score quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity.
SAPS is a self-assessment questionnaire of psoriasis symptoms.
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
| Arm | Type | Description |
|---|---|---|
| Substudy 2: Group 2 | EXPERIMENTAL | Participants with chronic plaque psoriasis will be administered with ABBV-157 dose D or matching placebo on Day 1 through Day 28 |
| Substudy 2: Group 1 | EXPERIMENTAL | Participants with chronic plaque psoriasis will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 28 |
| Substudy 1: Group 3 | EXPERIMENTAL | Participants, who are healthy volunteers, will be administered with ABBV-157 dose C or matching placebo on Day 1 through Day 14 |
| Substudy 1: Group 2 | EXPERIMENTAL | Participants, who are healthy volunteers, will be administered with ABBV-157 dose B or matching placebo on Day 1 through Day 14 |
| Substudy 1: Group 1 | EXPERIMENTAL | Participants, who are healthy volunteers, will be administered with ABBV-157 dose A or matching placebo on Day 1 through Day 14 |
| Name | Type | Description |
|---|---|---|
| ABBV-157 | DRUG | ABBV-157 will be administered orally as capsule |
| Placebo for ABBV-157 | DRUG | Placebo for ABBV-157 will be administered orally as capsule |
Inclusion Criteria: * Volunteer should be between 18 and 55 years of age and in general good health for Substudy 1 and participant with moderate to severe chronic plaque psoriasis between 18 and 75 years of age for Substudy 2 at the time of enrollment. * Participant should meet the laboratory asses...
ABBV-157 is an investigational small molecule being developed for the treatment of psoriasis, a chronic skin condition. It is currently in Phase 1 clinical development and has been studied in healthy volunteers and in participants with chronic plaque psoriasis.
The molecular target of ABBV-157 has not been disclosed. It is a small molecule being studied for its pharmacokinetics, safety, and tolerability in the treatment of psoriasis.
ABBV-157 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV.
ABBV-157 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
ABBV-157 has been studied in one completed Phase 1 trial, NCT03922607, which evaluated its pharmacokinetics, safety, and tolerability in healthy volunteers and participants with chronic plaque psoriasis. The trial enrolled 65 participants in the United States.
No alternative names for ABBV-157 have been disclosed. It is identified solely by its development code ABBV-157.